Cas 39562-70-4 Nitrendipine Agent Powder Hypertension Treatment

Product Description

Nitrendipine 99% Cas39562-70-4 API Antihypertensive original supplying 

New antihypertensive drug Nitrendipine is a new antihypertensive drug, chemical name is nitrophenyl ethylpyridine, belongs to dihydropyridine derivative, antihypertensive effect and nifedipine similar, but more effective, more lasting effect, up to 15 hours. Nirendipine is the second generation of dihydropyridine calcium antagonist, which is the most common 4 dihydropyridine calcium antagonist (nifedipine, amlodipine, felodipine) in clinical research, mainly used for the treatment of elderly hypertension and coronary heart disease. We know that the conventional method to treat high blood pressure is the guanidine b organism (blood pressure) and double hydrogen sulfate grams of urine (diuretic) combination and so on the one hand, double hydrogen grams of urine sodium by row diuresis, decreased blood volume, cardiac output decreases, on the other hand, direct inhibition of vascular smooth muscle, blood vessels and decrease peripheral vascular resistance causing blood pressure to drop, Therefore, combined with guanethidine sulfate, the antihypertensive effect was enhanced and the occurrence of edema was reduced. However, more potassium is excreted by dihydrocarbamate, which is easy to cause hypokalemia. However, if nitrendipine and dihydrocarbamate are used in combination, hypokalemia can be avoided. Because this product is excreted by urine sodium, not only helps the patient to reduce blood pressure, and it has the effect of inhibiting aldosterone release, so it does not cause hypokalemia. Pharmacological effects Nirendipine was first marketed in Germany in 1985 for the treatment of hypertension, congestive heart failure and hypertension with angina pectoris. It can selectively act on the calcium channel of vascular smooth muscle and inhibit the transmembrane calcium influx of vascular smooth muscle and myocardium. Its affinity for blood vessels is greater than that of myocardium, and its selective effect on coronary arteries is stronger. The order of arterial dilation intensity is: coronary artery > femoral artery > renal artery > pulmonary artery. It can reduce the oxygen consumption of myocardium and protect the ischemic myocardium. It can reduce the total peripheral resistance and reduce blood pressure. Oral absorption is good, but there is obvious first pass effect, F is 10% ~ 20%. PPB is 98%. Earlier studies reported t1/2 at 2h, while recent studies reported t1/2 at 10-22h due to the use of more sensitive measurement equipment. The oral Cmax was about 1.5h, and the systolic blood pressure began to decline after 30min, and the diastolic blood pressure began to decline after 60min. The antihypertensive effect reached its maximum within 1 ~ 2h and lasted for 6 ~ 8h. It is widely metabolized in the liver, 70% of its metabolites are excreted through the kidney and 8% are excreted in the stool. Serum drug concentration and elimination half-life were increased in patients with liver disease. Drug interactions (1) can increase plasma concentrations of digitalis, such as digoxin, by an average of about 45%. (2)β -receptor blocker: the vast majority of patients combined with this drug can strengthen the antihypertensive effect, and can reduce the tachycardia occurred after the product antihypertensive; However, individual patients have Chemicalbook that can induce and aggravate systemic hypotension, heart failure, and angina.